logo
  

Kering To Stop Using Animal Fur Starting Fall 2022 Collections

French luxury goods company Kering SA (PPRUY.PK,PPRUF.PK) announced Friday its decision to stop using animal fur.

Kering, which owns Gucci, Saint Laurent, Bottega Veneta, Balenciaga, and Alexander McQueen, among others, said none of its Houses will be using fur starting from the Fall 2022 collections.

In Paris, Kering shares were trading at 636.30 euros, down 2.60 percent.

In 2017, Gucci progressively decided to take this step, followed by all the company's Houses, notably Balenciaga, Bottega Veneta, Alexander McQueen, Brioni and Saint Laurent.

In 2019, Kering formalized and published a set of animal welfare standards that will continue to be applied, as they concern other animal fibers and materials.

François-Henri Pinault, Chairman and CEO of Kering, said, "When it comes to animal welfare, our Group has always demonstrated its willingness to improve practices within its own supply chain and the luxury sector in general. The time has now come to take a further step forward by ending the use of fur in all our collections."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
RELATED NEWS
Follow RTT